Edition:
United Kingdom

Ion Beam Applications SA (IBAB.BR)

IBAB.BR on Brussels Stock Exchange

24.01EUR
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
€24.01
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
129,483
52-wk High
€56.94
52-wk Low
€19.80

Latest Key Developments (Source: Significant Developments)

IBA 9-month revenues at 217.3 million euros, down 3.6% ‍​
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - ION BEAM APPLICATIONS SA ::9M REVENUES TO 30 SEPTEMBER 2017 OF EUR 217.3 MILLION, DOWN 3.6% ‍​.‍PROTON THERAPY AND OTHER ACCELERATORS ORDERS AT END OF Q3 TOTALLING EUR 76.7 MILLION​.EXPECTS FY17: 5-10% REVENUE GROWTH AND A 0-5% REBIT MARGIN.EXPECTS 2018/2019: 0-5% REVENUE GROWTH AND A 5-10% REBIT MARGIN.EXPECTS 2020 ONWARDS: 5-10% REVENUE GROWTH AND 13-15% REBIT MARGIN..DIVIDEND POLICY REMAINS UNCHANGED..‍REITERATES ITS GUIDANCE GIVEN AT TIME OF ITS HALF YEAR 2017 RESULTS​.DOSIMETRY BACKLOG AT END OF Q3 2017 WAS AT EUR 15.4 MILLION.DOSIMETRY ORDER INTAKE REMAINED STRONG AT EUR 39.4 MILLION AT END OF Q3 2017.NET NEGATIVE CASH POSITION OF EUR 2.5 MILLION AT END OF Q3 VERSUS POSITIVE NET CASH POSITION OF EUR 36.1 MILLION YEAR AGO‍​.  Full Article

IBA signs global construction collaboration with Vinci
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - ION BEAM APPLICATIONS SA ::IBA SIGNS GLOBAL CONSTRUCTION COLLABORATION WITH VINCI.‍FINANCIAL TERMS OF COLLABORATION ARE NOT DISCLOSED​.VINCI CONSTRUCTION WILL LEAD IN THE DESIGN OF THE BUILDING AND RELATED TECHNICAL ELEMENTS‍​.IBA WILL RETAIN LEAD OF THE DESIGN OF THE PROTON/CARBON THERAPY EQUIPMENT.  Full Article

Ion Beam Applications signs two contracts with Proton Partners International
Tuesday, 13 Dec 2016 

Ion Beam Applications SA : Typical end-user price for a Proteus ONE solution with a maintenance contract is between 35 million euros ($37.21 million) and 40 million euros .IBA signs two new Proteus ONE contracts with Proton Partners International.  Full Article

IBA signs contract to install Proteus One compact proton therapy center in Abu Dhabi
Tuesday, 27 Sep 2016 

Ion Beam Applications SA :Signs contract to install Proteus One compact proton therapy center in Abu Dhabi, UAE.  Full Article

IBA signs contract with Medstar for the purchase of a proton therapy system
Monday, 26 Sep 2016 

Ion Beam Applications SA :Announced on Sunday that it signed a contract with Medstar (Shanghai) Leasing Co., Ltd, a subsidiary of Concord Medical Services Holdings Limited, for the purchase, installation and maintenance of a proton therapy system.  Full Article

Ion Beam Applications H1 net profit down at 8.3‍​ million euros
Thursday, 25 Aug 2016 

Ion Beam Applications SA : H1 revenue 145.1‍​ million euros versus 121.0 million euros ($136.39 million) year ago . H1 rebitda 18.0‍​ million euros versus 14.6 million euros year ago .H1 net income 8.3‍​ million euros versus 14.5 million euros year ago.  Full Article

IBA invests 2 million US dollars in HIL Applied Medical Ltd.
Tuesday, 23 Aug 2016 

Ion Beam Applications SA : ‍​IBA invests in HIL Applied Medical Ltd. to develop laser-based proton therapy system .IBA has invested USD 2 million and is leading HIL’s series C round, together with other investors.  Full Article

IBA wins 80 mln euro plus contract in China
Wednesday, 29 Jun 2016 

Ion Beam Applications SA : Signs contract to install proton therapy center in China . Contract worth more than 80 million euros ($88.5 million) and includes a long term service contract . IBA will equip the new center with five treatment rooms, four isocentric-gantry treatment rooms and a fixed-beam treatment room .Qingdao Zhong Jia Lian He Healthcare Management Company Ltd expects to be treating patients at the center by the end of 2018.  Full Article

Ion Beam Applications appointed Soumya Chandramouli as CFO
Thursday, 2 Jun 2016 

Ion Beam Applications SA :Soumya Chandramouli appointed as chief financial officer.  Full Article

IBA cash position at end Q1 jumps to 104.9 mln euros
Wednesday, 11 May 2016 

Ion Beam Applications SA : Reports Q1 revenue of 64.6 million euros ($73.5 million), up 10.2 pct YoY . Guidance for 2016 reiterated for both topline growth and REBIT margin . Net cash position at end Q1 is 104.9 million euros versus 22.4 million euros at end of Q1 2015 . Sees 2016 revenue growth greater than 20 pct, with double digit annual growth thereafter . Sees 2016 operating margin of 11 pct, increasing to 13-15 pct by 2018 . Says is planning to maintain a dividend payout ratio of 30 pct .Proton therapy and other accelerators backlog amounts to 355.4 million euros at end Q1.  Full Article